サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：血液スクリーニングの世界市場-2023年～2030年
市場調査レポート
商品コード
1373367

血液スクリーニングの世界市場-2023年～2030年

Global Blood Screening Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 185 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
血液スクリーニングの世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 185 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

血液スクリーニング検査は、汚染された血液や血液成分が臨床用に流通するのを阻止するために、感染徴候を特定するために実施されます。血液スクリーニング検査は、疾患の症状がない人の潜在的な健康障害または疾患を検出するために行われます。

血液スクリーニング戦略は、血液ユニットの安全性を保証するために設計されていますが、反応性の検査結果を献血者に通知するために使用すべきではありません。血液スクリーニング検査には、次世代シーケンシング、核酸検査、ELISAなど様々な技術が使用されています。

市場力学

血液スクリーニング検査の増加

血液スクリーニング検査は、貴重な情報を提供し、特定の病状を診断するために血液サンプルに対して実施されます。血液スクリーニング検査の製品発売数の増加は、市場成長の重要な促進要因となっています。また、多くの重要な企業が新しい血液スクリーニング検査やキットを発売することで、市場の進歩に大きな役割を果たしています。

例えば、2023年10月、Delfi Diagnostics社は血液ベースの肺がんスクリーニング検査を発売しました。これは、より簡便な検出方法を提供し、現在の標準よりも多くの人々に到達できることを目的としています。

さらに、2023年8月、クエスト・ダイアグノスティックスは、米国でアルツハイマー病のAD-Detect検査を導入し、消費者が購入可能な初の血液ベースのバイオマーカー検査として、アルツハイマー病発症の潜在的リスクを評価できるようにしました。

さらに、世界の血液スクリーニング市場は、献血の増加のような様々な要因によって牽引され、感染症の発生率の増加が予測期間中の市場を牽引すると予想されます。

厳しい規制当局の承認と血液スクリーニング装置の高コスト

厳しい規制要件は、新しい血液スクリーニング技術や検査の承認や採用を遅らせる可能性があります。また、血液スクリーニング機器に関連する高コストは、市場の成長を妨げる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 血液スクリーニング検査の増加
      • 抑制要因
    • 抑制要因
      • 厳しい規制当局の承認と血液スクリーニング機器の高コスト
      • YY
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • DMI意見

第6章 COVID-19分析

第7章 製品タイプ別

  • インスツルメンツ
    • アウトライト購入
    • レンタル購入
  • 試薬・キット
    • NAT試薬＆キット
      • スタンダード＆コントロール
      • 標識および検出試薬
      • 酵素とポリメラーゼ
      • プローブとプライマー
      • バッファー、ヌクレオチド、溶液
    • ELISA試薬＆キット
      • コンジュゲート（抗原または抗体-コンジュゲート酵素）
      • 免疫吸着剤
      • コントロール
      • 基質
      • サンプル希釈液および洗浄液
      • その他の試薬

第8章 テクノロジー別

  • 次世代シーケンサー（NGS）
  • 次世代シーケンサー（NGS）
    • リアルタイムポリメラーゼ連鎖反応（PCR）
    • 転写媒介増幅（TMA）
  • 酵素結合免疫吸着測定法（ELISA）
    • ELISA、プラットフォーム別
      • 蛍光免疫測定法（FIA）
      • 化学発光免疫測定法（CLIA）
      • 比色免疫測定法（CI）
    • ELISA、世代別
      • 第一世代ELISA
      • 第二世代ELISA
      • 第三世代ELISA
      • 第四世代以上
  • ウェスタンブロットアッセイ
  • 迅速検査
  • その他

第9章 エンドユーザー別

  • 病院
  • 血液銀行
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Bio-Rad Laboratories, Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Grifols
  • Abbott Laboratories
  • F. Hoffmann-La Roche
  • Siemens Healthineers
  • Biomerieux
  • Thermo Fisher Scientific, Inc.
  • Ortho Clinical Diagnostics, Inc.
  • Becton, Dickinson, and Company
  • Beckman Coulter（Danaher Corporation）

第13章 付録

目次
Product Code: CD1618

Overview

Blood screening tests are performed to identify infection signs in order to stop the distribution of contaminated blood and blood components for clinical use. A blood screening test is done to detect potential health disorders or diseases in people who do not have any symptoms of the disease.

Blood screening strategies are designed to assure the safety of blood units, but should not be used for notifying blood donors of reactive test results. Various technologies are used in blood screening tests which include next-generation sequencing, nucleic acid tests, and ELISA.

Market Dynamics

Increasing launches of blood screening tests

Blood screening tests are performed on a blood sample to provide valuable information and diagnose specific medical conditions. The increasing number of product launches for blood screening tests acts as a significant driver for market growth. Also, many significant companies play a major role in the advancements of the market by launching new blood screening tests and kits.

For instance, in October 2023, Delfi Diagnostics launched a blood-based lung cancer screening test. It aims to provide a more convenient detection method and one that's capable of reaching a greater number of people than the current standard.

Additionally, in August 2023, Quest Diagnostics introduced its AD-Detect test for Alzheimer's disease in the United States by making it the first blood-based biomarker test available for consumers to purchase and assess the potential risks of developing Alzheimer's disease.

Furthermore, the global blood screening market is driven by various factors like rising blood donations, and an increase in the incidence of infectious diseases is expected to drive the market in the forecast period.

The stringent regulatory approvals and high cost of blood screening equipment

Stringent regulatory requirements can slow the approval and adoption of new blood screening technologies or tests. Also, the high cost associated with blood screening equipment can hamper the market growth.

Segment Analysis

The global blood screening market is segmented based on product type, technology, end users, and region.

Reagents and kits accounted for approximately 48.4% of the market share

The anti-A, anti-B, and anti-A, B reagents are used in the red blood cell determination of the ABO blood group. They are used to determine the absence or presence of erythrocytic antigens A or B on the surface of human red blood cells. Reagents and kits are expected to hold the largest market share over the period forecast owing to the high requirement for reagents, kits, and product launches.

For instance, in June 2023, Sysmex launched an assay kit to identify Amyloid Beta (AB) accumulation in the brain that causes Alzheimer's disease by using a small amount of blood.

Additionally, in July 2021, Ortho Clinical Diagnostics launched its VITROS Immunodiagnostic Products IL-6 Reagent Pack which is the latest addition to Ortho's VITROS Critical Care blood screening menu.

Geographical Analysis

North America is expected to hold a significant position in the global blood screening market share

The global blood screening market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising blood transfusion rates, and product launches, this trend is anticipated to continue throughout the forecast period.

For instance, according to the American Red Cross, in the United States, an estimated 10,000 units of plasma, roughly 7,000 units of platelets, and 36,000 units of red blood cells are needed per day. In the United States, more than 21 million blood components are transfused annually.

Additionally, in September 2023, Oxford BioDynamics, Plc. Launched its 94% accurate EpiSwitch prostate screening blood test for men with prostate cancer risk.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global blood screening market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the blood screening market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Bio-Rad Laboratories, Inc., Grifols S.A, Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Biomerieux, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, Inc., Becton, Dickinson, and Company, Beckman Coulter (Danaher Corporation). Among others.

Key Developments

  • In March 2023, H.U. Group Holdings Inc. introduced the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light (NfL) in human cerebrospinal fluid (CSF) and plasma.
  • In June 2021, Grail launched the Galleri blood screening test which is a multi-cancer screening capable of detecting many cancers.

Why Purchase the Report?

  • To visualize the global blood screening market segmentation based on product type, technology, end users and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of blood screening market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global blood screening market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing launches of blood screening tests
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. The stringent regulatory approvals and high cost of blood screening equipment
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Outright Purchase
    • 7.2.4. Rental Purchase
  • 7.3. Reagents & Kits
    • 7.3.1. NAT Reagents & Kits
      • 7.3.1.1. Standards and Controls
      • 7.3.1.2. Labeling and Detection Reagents
      • 7.3.1.3. Enzymes and Polymerases
      • 7.3.1.4. Probes and Primers
      • 7.3.1.5. Buffers, Nucleotides, and Solutions
    • 7.3.2. ELISA Reagents & Kits
      • 7.3.2.1. conjugates (Antigen Or Antibody-Conjugated Enzyme)
      • 7.3.2.2. Immunosorbents
      • 7.3.2.3. Controls
      • 7.3.2.4. Substrates
      • 7.3.2.5. Sample Diluents and Wash Solutions
      • 7.3.2.6. Other Reagents

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Next-Generation Sequencing (NGS) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Next-Generation Sequencing (NGS)
    • 8.3.1. Real-Time Polymerase Chain Reaction (PCR)
    • 8.3.2. Transcription-Mediated Amplification (TMA)
  • 8.4. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 8.4.1. ELISA, By Platform
      • 8.4.1.1. Fluorescence Immunoassay (FIA)
      • 8.4.1.2. Chemiluminescence Immunoassay (CLIA)
      • 8.4.1.3. Colorimetric Immunoassay (CI)
    • 8.4.2. ELISA, By Generation
      • 8.4.2.1. First-Generation ELISA
      • 8.4.2.2. Second-Generation ELISA
      • 8.4.2.3. Third-Generation ELISA
      • 8.4.2.4. Fourth-Generation & Above
  • 8.5. Western Blot Assay
  • 8.6. Rapid Tests
  • 8.7. Others

9. By End Users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.1.2. Market Attractiveness Index, By End Users
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Blood Banks
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bio-Rad Laboratories, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Grifols
  • 12.3. Abbott Laboratories
  • 12.4. F. Hoffmann-La Roche
  • 12.5. Siemens Healthineers
  • 12.6. Biomerieux
  • 12.7. Thermo Fisher Scientific, Inc.
  • 12.8. Ortho Clinical Diagnostics, Inc.
  • 12.9. Becton, Dickinson, and Company
  • 12.10. Beckman Coulter (Danaher Corporation)

LIST NOT EXHAUSTIVE.

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us